CNMD Quote, Financials, Valuation and Earnings

Escalon Medical Corp. has a net margin of 4.49% compared to CONMED Corp.'s net margin of -8.97%. CONMED Corp.'s return on equity of 6.56% beat Escalon Medical Corp.'s return on equity of -5.28%.

CONMED Corp. has a consensus price target of $47.40, signalling upside risk potential of 14.16%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 6581.52%. Given that Escalon Medical Corp. has higher upside potential than CONMED Corp., analysts believe Escalon Medical Corp. is more attractive than CONMED Corp..

CONMED Corp. has a beta of 0.967, which suggesting that the stock is 3.283% less volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.1%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.93%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $373.2M, which are larger than Escalon Medical Corp. quarterly revenues of $2.7M. CONMED Corp.'s net income of $16.7M is higher than Escalon Medical Corp.'s net income of -$239.9K. Notably, CONMED Corp.'s price-to-earnings ratio is 27.39x while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 0.94x versus 0.16x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guided Therapeutics, Inc. has a net margin of 4.49% compared to CONMED Corp.'s net margin of -1236.67%. CONMED Corp.'s return on equity of 6.56% beat Guided Therapeutics, Inc.'s return on equity of --.

CONMED Corp. has a consensus price target of $47.40, signalling upside risk potential of 14.16%. On the other hand Guided Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 28006901.75%. Given that Guided Therapeutics, Inc. has higher upside potential than CONMED Corp., analysts believe Guided Therapeutics, Inc. is more attractive than CONMED Corp..

CONMED Corp. has a beta of 0.967, which suggesting that the stock is 3.283% less volatile than S&P 500. In comparison Guided Therapeutics, Inc. has a beta of 0.606, suggesting its less volatile than the S&P 500 by 39.441%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.93%. Guided Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Guided Therapeutics, Inc. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $373.2M, which are larger than Guided Therapeutics, Inc. quarterly revenues of $60K. CONMED Corp.'s net income of $16.7M is higher than Guided Therapeutics, Inc.'s net income of -$742K. Notably, CONMED Corp.'s price-to-earnings ratio is 27.39x while Guided Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 0.94x versus 163.08x for Guided Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of 4.49% compared to CONMED Corp.'s net margin of -12.6%. CONMED Corp.'s return on equity of 6.56% beat IRIDEX Corp.'s return on equity of -155.93%.

CONMED Corp. has a consensus price target of $47.40, signalling upside risk potential of 14.16%. On the other hand IRIDEX Corp. has an analysts' consensus of $3.00 which suggests that it could grow by 105.48%. Given that IRIDEX Corp. has higher upside potential than CONMED Corp., analysts believe IRIDEX Corp. is more attractive than CONMED Corp..

CONMED Corp. has a beta of 0.967, which suggesting that the stock is 3.283% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.514%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.93%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $373.2M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. CONMED Corp.'s net income of $16.7M is higher than IRIDEX Corp.'s net income of -$1.6M. Notably, CONMED Corp.'s price-to-earnings ratio is 27.39x while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 0.94x versus 0.48x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.